Dr. Blair Phillip Peoples, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 1300 W 7th St, San Pedro, CA 90732 Phone: 310-241-2500 |
Kamran Ghadimi, M.D. Anesthesiology - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 1412 W 7th St, San Pedro, CA 90732 Phone: 310-548-5481 Fax: 310-548-5000 |
Denise D. Brathwaite, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 1300 W 7th St, San Pedro, CA 90732 Phone: 310-832-3311 |
Ricardo Jesus Aguirre, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1300 W 7th St, San Pedro, CA 90732 Phone: 310-792-0601 |
News Archive
Treatment of depression is difficult for both patients and for psychiatrists. While there are numerous drugs available that work, finding the right one - or right combination - is, at times, a matter of trial and error.
GOT YOUR BACK will be hosting an Open House at their retail location at 521 East Hector Street, Conshohocken, PA on December 12th from 1:00 p.m. - 4:00 p.m. Guests will include health and wellness professionals, chiropractors, massage therapists and those interested in alternative fitness and wellness throughout the tri-state area. Visitors will enjoy food, beverages, a free chair massage, and free on site diagnosis of the spine. This event is also open to the public and special discounts will be offered throughout the store exclusively for attendees of this event.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded nearly $9.7 million over five years to the Radiation Effects Research Foundation (RERF), Japan, to study the effects of atomic bomb radiation and aging on the human immune system.
Scientists have discovered that mutations in the histone deacetylase 8 gene can cause the rare genetic disorder known as Cornelia de Lange syndrome, which is characterized by intellectual disability, limb deformity, and other disabilities resulting from problems in early development.
GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.
› Verified 2 days ago